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Abstract. The involvement of p53 protein in cell differ- 
entiation has been recently suggested by some observa- 
tions made with tumor cells and the correlation found 
between differentiation and increased levels of p53. 
However, the effect of p53 on differentiation is in ap- 
parent contrast with the normal development of p53- 
null mice. To test directly whether p53 has a function in 
cell differentiation, we interfered with the endogenous 
wt-p53 protein of nontransformed cells of two different 
murine histotypes: 32D myeloid progenitors, and 
C2C12 myoblasts. A drastic inhibition of terminal dif- 
ferentiation into granulocytes or myotubes, respec- 
tively, was observed upon expression of dominant-neg- 
ative p53 proteins. This inhibition did not alter the cell 
cycle withdrawal typical of terminal differentiation, nor 
p21 (wAF1/cIP1) upregulation, indicating that interference 
with endogenous p53 directly affects cell differentia- 
tion, independently of the p53 activity on the cell cycle. 
We also found that the endogenous wt-p53 protein of 
C2C12 cells becomes transcriptionally active during 
myogenesis, and this activity is inhibited by p53 domi- 
nant-negative expression. Moreover, we found that p53 
DNA-binding and transcriptional activities are both re- 
quired to induce differentiation in p53-negative K562 
cells. Taken together, these data strongly indicate that 
p53 is a regulator of cell differentiation and it exerts 
this role, at least in part, through its transcriptional ac- 
tivity. 
T 
HE wt-p53 gene encodes a nuclear phosphoprotein 
which  has  many properties  of tumor  suppressors 
(Finlay et al., 1989; Baker et al.,  1990; Chen et al., 
1990). Mutations or inactivation of p53 are frequently as- 
sociated with a large number of human cancers (Baker et 
al.,  1989; Levine et al., 1991). Biochemical and molecular 
studies demonstrated that p53  is able to bind to specific 
DNA sequences (Kern et al., 1991)  and to activate gene 
transcription (Farmer et al.,  1992). However, the biologi- 
cal functions of p53 are still debated. Increased expression 
of endogenous p53 protein was observed during the cellu- 
lar  response  to  X-ray  or  drug-induced  DNA  damage 
(Kastan et al., 1991b;  Kuerbitz et al., 1992; Lowe et al., 
1993a,b; Lu and Lane, 1993). These increased levels of p53 
protein seem to be responsible for an increased transcrip- 
tion of the p21 (wAF1/clP1) inhibitor of cyclin-dependent ki- 
nases and the consequent growth arrest in the G1 phase of 
the  cell cycle that allows DNA  repair  (EI-Deiry et  al., 
1993; Dulic et al., 1994). It was also shown that wt-p53 is 
required  for  the  apoptosis  induced  by  DNA  damage 
(Lowe et al., 1993b; Gottlieb et al., 1994; Morgenbesser et 
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al.,  1994),  and for the maintenance of genomic stability 
(Livingstone et al.,  1992; Yin et al., 1992).  Although the 
functional deletion of the p53 gene, obtained by homolo- 
gous recombination, showed that p53 function is dispens- 
able for embryonic development (Donehower et al., 1992), 
several studies suggested that p53 plays a role in the regu- 
lation of cell differentiation (for review see Prokocimer 
and Rotter,  1994).  A  correlation between increased ex- 
pression of endogenous p53 protein and some physiologi- 
cal differentiative processes, such as hematopoiesis (Kas- 
tan et al., 1991a) and spermatogenesis (Almon et al., 1993) 
was observed. Furthermore, overexpression of exogenous 
wt-p53 protein as well as cell-irradiation can partially re- 
store differentiation of several tumor cells (Shaulsky et al., 
1991; Feinstein et al., 1992; Brenner et al., 1993; Soddu et 
al., 1994, Aloni-Grinstein et al., 1995). However, data ob- 
tained in tumor cells cannot demonstrate a p53 role in cell 
differentiation (Kemp et al., 1993) since as a tumor sup- 
pressor, wt-p53 may inhibit transformation by normalizing 
tumor cells; the latter might re-acquire the capacity to dif- 
ferentiate as a mere consequence of this normalization. 
The availability of dominant-negative proteins for p53 
offers the possibility to  directly test whether p53  has  a 
function in cell differentiation. In this paper we interfere 
with the endogenous wt-p53  protein  of nontransformed 
ceils such as 32D myeloid precursors or C2C12 myoblasts, 
which can terminally differentiate into granulocytes and 
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Saxel, 1977; Blau et al., 1985). Inactivation of the endoge- 
nous p53  protein  is  obtained  by overexpression  of the 
dominant-negative  mutants  p53Val ~35  or  DD-p53-mini- 
protein (Milner and Medcalf, 1991; Shaulian et al., 1992). 
The morphological and biochemical analyses performed 
on cells induced to differentiate show a striking reduction 
in the ability of the transfected cells to mature into granu- 
locytes or myotubes, demonstrating a direct p53  involve- 
ment in cell differentiation. Interference with endogenous 
p53 protein does not alter the typical cell cycle modifica- 
tions induced by either hemopoietic or muscle differentia- 
tion processes, including p21 (wAF1/cIP1) upregulation; this 
indicates that wt-p53 contributes to cell differentiation in- 
dependently of its activity on the cell cycle. 
We find that stimulation of C2C12 differentiation asso- 
dates with a dramatic induction of endogenous p53 tran- 
scriptional activity and this activity appears to be neces- 
sary to induce cell differentiation in the p53-negative K562 
cells. 
This study strongly indicates that p53 is involved in he- 
matopoietic and muscle differentiation. 
Materials and Methods 
Cells and Culture Conditions 
32Dcl.3  murine hematopoietic precursor cells were cultured in RPMI- 
1640 medium (Bio-Whittaker, Inc., Walkersville, MD) supplemented with 
10%  heat-inactivated FBS (GIBCO BRL, Grand Island, NY), and 5% 
conditioned medium from the murine myelomonocytic cell line WEHI-3B 
as a  source of crude interleukin-3 (IL-3) 1 (Lee et al., 1982).  To induce 
granulocytic differentiation, 32D ceils were cultured in RPMI-1640 with 
10%  conditioned medium from the human glioblastoma cell line U-87 
MG as a source of crude granulocyte-colony stimulating factor (G-CSF) 
(Mavilio et al., 1989). This differentiation medium was replaced every 3 d. 
C2C12 murine myoblast cells were cultured in DMEM (Bio-Whittaker) 
supplemented with 10%  FBS  growth medium (GM). These cells were 
used within passage 30 since their differentiation index (see later in this 
section) can decrease significantly after this passage. To avoid spontane- 
ous differentiation the cells are not allowed to reach confluency. Muscle 
differentiation was  induced by incubation  in  serum-free medium (SF) 
(DMEM supplemented with l0 ixg/ml insulin, and 5 p,g/ml transferrin), as 
described (Crescenzi et al., 1994). Briefly, C2C12  cells, or their transfec- 
tants, in logarithmic phase of proliferation were trypsinized and plated on 
Petri dishes at a concentration of '-~5.2 x  103 cell/era  2. After 2-3 h at 37°C, 
the adherent cells were washed with PBS, and SF medium was added and 
replaced every 48 h. For the experiments conducted at 32°C, the ceils were 
let to adhere at 37°C and then shifted at 32°C for 24 h before incubation in 
SF medium. For the experiments conducted at 39.5°C, the cells were main- 
tained constantly at this temperature and processed as decribed for 37°C. 
K562 human leukemia cells were cultured in P,  PMI-1640 supplemented 
with 10% heat-inactivated FBS. 
Plasmids and Transfections 
The following plasmids were used for transfection: p53cG(Va1135),  carry- 
ing the temperature-sensitive p53Va1135 mutant gene under the control of 
the HaMSV-LTR; pN53cG(Val135),  obtained by cloning the selectable 
marker neo under the control of the RSV-LTR into the p53cG(Val135); 
pRSVneo, carrying the selectable marker for G418 resistance under the 
control of the RSV-LTR; pBabe-puro, carrying the selectable marker for 
puromycin resistance under the control of the SV40 late-promoter (kindly 
provided by H. Land, Imperial Cancer Research Fund Laboratories, Lon- 
don, UK); pCMV-DD, carrying the dominant-negative p53 miniprotein 
under the control of the CMV promoter (kindly provided by M. Oren, 
1. Abbreviations used in this paper: G-CSF, granulocyte-colony stimulat- 
ing factor; GM, growth medium; IL-3, interleukin-3; MHC, myosin heavy 
chain; SF, serum-free. 
Weismann Institute, Rehovst, Israel); PGlaCAT, carrying the CAT re- 
porter gene driven by polyoma virus promoter and 13 copies of the p53 
consensus-binding sequence, or MGlsCAT with 15 copies of a p53 non- 
binding site (Kern et al., 1992) (kindly provided by B. Vogelstein, Johns 
Hopkins Oneology Center, Baltimore, MD); and pMSV-val135-22/23,  car- 
rying the temperature-sensitive p53Va1135 mutant with a second, double 
mutation at the transacting domain which inhibits the transcriptional ac- 
tivity (Hinds et al., 1989; Lin et al., 1994) (kindly provided by A.J. Levine, 
Princeton University, Princeton, NJ). 
Approximately 5  ×  106 exponentially growing 32D cells were trans- 
fected by electroporation (0.2 KV, 960 p,F) with a Gene Pulser (Bio-Rad 
Laboratories Inc., Hercules,  CA). 48  h  after gene transfer, cells were 
cloned by limiting dilution in selection medium containing 1 mg/ml G418 
(GIBCO BRL) or 2 Ixg/ml puromycin. 32D cells were cotransfected with 
the expression vectors p53cG(val135) and pBabe-puro (32Dtsp53#8  and 
32Dtsp53#10),  or with pCMV-DD  and  pBabe-puro  (32D-DD#2,  32D- 
DD#4, 32D-DD#10, and 32D-DD#13). pBabe-puro was transfected alone 
(32Dpuro#1) as a control. 
Approximately 2  X 106 exponentially growing C2C12  cells were elec- 
troporated (0.25  KV, 960  txF), grown in mixed culture or plated at low 
density for clone isolation, and maintained in selection medium containing 
0.75 mg/ml G418 or 3 ixg/ml puromycin for three weeks. C2C12 cells were 
cotransfected with  expression vectors  p53cG(val135)  and  pBabe-puro 
(C2-tsp53#15,  C2-tsp53#16,  and  C2-tsp53#17)  or with pN53cG(Val135) 
(C2-tsp53 Mix). As control pBabe-puro (C2-puro#2) or pRSV-neo (C2- 
neo Mix) were transfected alone. C2C12 cells were also cotransfected with 
pBabe-puro and PG13-CAT (PG-cat#6, PG-cat#15) or MG15-CAT (MG- 
cat#3, MG-cat#7). The CAT gene integration was assessed on cell lysates 
by polymerase chain reaction (Soddu et al., 1994) using two primers com- 
plementary to the CAT sequence (5'-GTCAGTTGCTCAATI'GTAAC-3'; 
3'-GGCCGTCAAAGATGTGTATA-5'). 
PG-cat#6 and PG-cat#15 cells were stably transfected, as described for 
the parental C2C12  cells, with pN53cG(Val135)  (PG-cat#6-tsp53.8 and 
PG-cat#15-tsp53.7) or pRSVneo (PG-cat#6-neo.1). 
K562 ceils were stably transfected by electroporation with the expression 
vectors pN53cG(va1135)  (K-tsp53#7, K-tsp53#10,  K-tsp53#12,  K-tsp53#14), 
pMSV-val135-22/23  (K-ts22-23#7,  K-ts22-23#8,  K-ts22-23#10,  K-ts22- 
23#12), or pRSV-neo (K-neo#1). 
Viruses and Infection 
The recombinant adenovirus AdJL16 (Bacchetti and Graham, 1993) car- 
rying the human wt-p53 (kindly provided by S. Bacchetti, McMaster Uni- 
versity,  Hamilton,  Ontario),  and  the  replication-defective, El-deleted 
d1312 control adenovirus (Jones and Shenk, 1979), were prepared and ti- 
trated by infection of 293 cells. Adherent C2C12 cells were infected with 
20 p.f.u./cell as described (Crescenzi et al., 1995).  Differentiation induc- 
tion was performed as described for parental and transfected cells starting 
at 24-h postinfection. 
Immunoprecipitation 
Approximately 106 C2C12  cells were labeled in 3 ml of methionine-free 
medium containing 100 p,  Ci/ml of [35S]methionine  (Dupont/New England 
Nuclear Italiana s.p.a. Milano, Italy) and 1% dialyzed FBS for 90 min. 
Cells were washed three times in cold phosphate-buffered saline (PBS) 
(150 mM NaCl; 50 mM NaH2PO  4, pH 7.5) and incubated for 30 rain on ice 
in lysis buffer (150 mM NaC1; 50 mM Tris, pH 8; 5 mM EDTA; 1% NP-40; 
1 mM PMSF). The lysates were centrifuged at 100,000 g for 30 rain and the 
pellets were discarded. Lysates containing equivalent amounts of proteins 
were subjected to immunoprecipitation by incubation for 90 min at 4°C 
with anti-p53 monoclonal antibodies PAb246 (Oncogene Science, Union- 
dale, NY) or PAb240 (kindly provided by A. Giordano, Thomas Jefferson 
University, Philadelphia, PA). Immunocomplexes were precipitated with 
ImmunopurePlus  protein  A  (Pierce  Europe  B.V.,  The  Netherlands) 
bound to  a  rabbit  anti-mouse IgG  antiserum  (USB,  Cleveland, OH), 
washed four times with lysis buffer, boiled for 5 min in sample buffer, ana- 
lyzed on 10% SDS-PAGE, and subjected to fluorography. 
Western Blotting 
Approximately 5  ×  106 cells were incubated for 30 min on ice in lysis 
buffer (20 mM Tris, pH 7.8; 50 mM NaC1; 5 mM EDTA; 1% Triton X-100; 
0.2%  SDS; 0.5% sodium deoxycholate; 1 mM PMSF). The lysates were 
centrifuged at  100,000  g for 30 min, and the pellets were discarded. A 
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and  blotted  onto  nitrocellulose membranes (Bio-Rad).  After blocking 
nonspecific reactivity by rocking for 1 h at RT in 2% nonfat dry milk dis- 
solved in TBST (20 mM Tris-HC1 pH 7.8, 150 mM NaCI, 0.02%  Tween 
20), filters were probed rocking for 2 h  at RT with anti-p53 PAb240 or 
PAb-7 (Oncogene Science) diluted in TBST. Immunoreactivity was deter- 
mined using the DAB-reaction or ECL-reaction kit  (Amersham Corp., 
Arlington Heights, IL), following the manufacturer's instructions. 
Indirect Immunofluorescence 
Approximately 5  ×  104 C2C12 cells were plated on 35-mm Petri dishes. 
For p53Va1135 protein detection, cells were fixed with absolute methanol 
at -20°C for 30 min, rehydrated and preblocked for 30 min at RT in PBS 
containing 3% FBS, and incubated for 1 h  at 37°C with moAb PAb122 
(Boehringer-Mannheim Italia  s.p.a., Milano,  Italy),  which recognizes a 
conserved, denaturation stable epitope in the COOH-terminal region of 
p53 protein.  For myosin heavy chain (MHC) detection, cells were fixed 
with cold methanol:acetone (1:1) for 10 min, rehydrated, and incubated 
for 1 h  at 37°C with moAb MF20 (Bader et al., 1982).  Immunoreactions 
were detected by incubation with an affinity-purified, fluorescein isothio- 
cyanate (FITC)-conjugated, goat anti-mouse-IgG (FAb)2 fragment (Cap- 
pel, West Chester, PA). Nuclei were stained after immunofluorescence  re- 
action  by  incubating  the  cells  for  3  min  in  a  1-mg/ml  solution  of 
HOECHST 33258 dye in PBS. 
Determination of Cell Differentiation 
Granulocytic differentiation was assessed by morphological analysis of 
cytospin  preparations  fixed  and  stained  with  May-Grunwald  Giemsa 
(Sigma Chem. Co., St. Louis, MO). 200 cells were counted from each sam- 
ple by a light microscope. 
Skeletal muscle differentiation was detected by indirect immunofluo- 
rescence for MHC. Differentiation index was calculated at the indicated 
time points, by counting 200 nuclei per dish, as follows: 
Number of nuclei in differentiated  cells  Differentiation  index = 
Total number of nuclei 
Erythroid  differentiation was assessed by benzidine staining for  the 
presence of hemoglobin. Benzidine stain was freshly prepared by mixing 
1 ml of stock benzidine hydrochloride (Sigma) (2 mg/ml in 0.5%  acetic 
acid) with 5  pA of 30%  hydrogen peroxide. Equal volumes of benzidine 
stain  were  thoroughly  mixed  with  cell  suspensions, transferred  to  a 
hemocytometer, and cells were scored after 5 min. 400 cells were counted 
from each sample. 
Cell Cycle Analysis, Proliferation, and Viability Curves 
32D cells, 5 ×  105, were fixed in cold acetone:methanol (1:4) for 30 min at 
4°C, and DNA was stained with 50  Ixg/ml propidium iodide  (Sigma) in 
PBS with 1 mg/ml RNAse A  (Boehringer-Mannheim) for 30 rain at RT. 
The DNA content was measured by an Epics XL analyzer (Coulter Cor- 
poration, Miami, FL). C2C12 cells, 105, were plated in 60-mm Petri dishes 
in either GM or SF. Cell numbers were determined in duplicate, at daily 
intervals. The means of three experiments are presented.  Cell viability 
was determined by trypan blue exclusion test. 
Northern Blot Hybridization 
Total cellular RNA was extracted by the guanidium thiocyanate method 
(Chomczynski and Sacchi, 1987).  Aliquots of 15 ~g per lane were electro- 
phoresed through 1.5% agarose gel in the presence of formaldehyde. Gels 
were  blotted  onto  Duralose  nitrocellulose  membrane  (Stratagene,  La 
Jolla,  CA) and hybridized as described (Ausubel et al.,  1987).  The p21 
probe was a  gel-purified 0.8-kb fragment of murine p21  eDNA (kindly 
provided by C. Schneider, Consortium for Interuniversity Biology, Padri- 
ciano 99, Italy) labeled with [32p]dCTP (Dupont/New England Nuclear) 
by random primer extension (Ausubel et al., 1987). 
CAT Analysis 
Approximately 105 C2C12 cells were plated in 60-mm dishes and differen- 
tiation was induced by SF. Cells were lysed at the indicated times after se- 
rum withdrawal. The amount of CAT protein was evaluated by using a 
CAT-ELISA  kit  (Boehringer-Mannheim) following the manufacturer's 
instructions. 
Results 
Dominant-negative p53 Proteins Inhibit Granulocytic 
Differentiation of 32D Cells 
To evaluate whether p53 protein is dispensable for cell dif- 
ferentiation of nontransformed cells, we used the domi- 
nant-negative effect of the p53Va1135 mutant (Milner and 
Medcalf, 1991) and the DD-p53  miniprotein (Shaulian et 
al., 1992) to interfere with the endogenous wt-p53 protein 
of 32D  myeloid precursor  cells.  These  are  IL-3-depen- 
dent, diploid cells (Greenberger et al., 1983a, b), which do 
not spontaneously develop IL-3 independence (Askew et 
al.,  1991),  and  do  not  induce  tumors  in  syngenic mice 
(Migliaccio et al., 1989). 32D cells express a wt-p53 protein 
(Blandino et al., 1995) and differentiate through the gran- 
ulocytic pathway in the presence of G-CSF (Valtieri et al., 
1987). p53Va1135 is a temperature-sensitive protein which 
has a mutant configuration at 37°C but behaves like wt- 
p53 at 32°C (Michalovitz et al., 1990). In the mutant con- 
figuration, p53Va1135 protein has a dominant-negative ef- 
fect over wt-p53 protein (Milner and Medcalf, 1991). The 
DD-p53 miniprotein consists of the last 89 residues of mu- 
rine  wt-p53,  includes  the  oligomerization  domain,  and 
lacks the DNA-binding and -transacting domains. An an- 
tagonist effect of DD-p53  toward a  coexpressed  wt-p53 
protein has been reported, at least partially due to the for- 
mation of functionally defective, mixed oligomers between 
the  two proteins  (Shaulian et al.,  1992).  We transfected 
32D cells as described in Materials and Methods, and sin- 
gle cell clones were analyzed for dominant-negative p53 
protein-expression by Western blotting (Fig.  1).  Two of 
the  strongest p53Val135-positive  clones  (32Dtsp53#8  and 
32Dtsp53#10),  four  DD-p53-positive  ones  (32D-DD#2, 
Figure 1.  Biochemical analysis of transduced p53Va1135 and DD 
proteins.  Cell lysates deriving from the indicated cells, and con- 
taining equal amounts of proteins were  separated on a  denatur- 
ing,  12.5%  polyacrylamide  gel.  Western  blot  analysis was  per- 
formed  with  moAb  PAb240.  The  positions  of p53  protein  and 
DD miniprotein are indicated. 
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mycin-resistant clone (32Dpuro#1) were selected for the 
following experiments. The 32Dtsp53#6  and  32Dneo#12 
clones, described elsewhere (Blandino et al.,  1995), which 
carry the p53Va1135 and neo genes or the neo gene alone, 
were also used.  As  already reported for other cell lines 
(Shaulian et al., 1992;  Gottlieb et al., 1994), the DD-p53 
transfectants expressed an increased amount of the endog- 
enous  p53  protein,  probably due  to  its  stabilization  in- 
duced  by the  formation of wt-p53  and  DD-miniprotein 
hetero-oligomers. 
Expression  of  p53Va1135 mutant  at  37°C  or  DD-p53 
miniprotein  did  not  confer  IL-3  independence  to  32D 
cells, nor a proliferative advantage in the presence of IL-3, 
while they protect from apoptosis  after IL-3 withdrawal 
(Gottlieb et al.,  1994; Blandino et al.,  1995; Blandino, G., 
and S. Soddu, unpublished results). In contrast, when the 
dominant-negative expressing cells were stimulated to dif- 
ferentiate by G-CSF,  a  strong inhibition of granulocytic 
differentiation was observed. As expected, after 8 d in the 
presence of G-CSF,  ~80%  of parental,  puro-  and  neo- 
transfected 32D controls presented a  decreased nuclear: 
cytoplasmic ratio,  less  basophilic cytoplasm, less  promi- 
nent  nucleoli,  segmented  and  pluri-segmented  nuclei, 
which  are  the  typical  morphological  characteristics  of 
granulocytes.  In  contrast,  differentiation was  almost  ab- 
sent in p53Va1135- and DD-p53-expressing cells (Fig. 2 A). 
This inhibition was quantified by calculating the percent- 
ages of cells in the undifferentiated, partially matured, and 
terminally differentiated stages of maturation (Fig. 2 B). 
These results show that the inactivation of wt-p53 func- 
tion suppresses cytokine-induced granulocytic maturation 
of 32D  cells,  thus indicating that  p53 is  involved in  he- 
matopoietic differentiation. 
Dominant-negative p53 Inhibits Skeletal 
Muscle Differentiation 
To evaluate whether inhibition of differentiation by inter- 
ference with wt-p53 is limited to hematopoietic cells, or it 
is a more general phenomenon, we overexpressed p53Va1135 
mutant in a  different histotype, the skeletal muscle. The 
myoblasts  of the  C2C12  murine  cell  line  are  nontrans- 
formed cells  that,  upon  serum  withdrawal,  differentiate 
initially into mononucleated myocytes and eventually fuse 
into  multinucleated  myotubes  (Yaffe  and  Saxel,  1977; 
Blau et al.,  1985).  We first verified the status of endoge- 
nous p53 protein by immunoprecipitation with the moAb 
PAb246,  which  reacts  selectively with  p53  in  wild-type 
conformation, and  with  PAb240,  which  reacts  with  p53 
mutant  forms  (Gannon  et  al.,  1990).  Only PAb246  was 
able  to  recognize p53  protein  from C2C12  cell  lysates, 
showing that C2C12 cells express an ostensibly wt-p53 pro- 
tein (Fig. 3). The wild-type conformation of this p53 was 
also confirmed by its transcriptional activity (see below). 
Clones  of  C2C12  cells  expressing  dominant-negative 
p53 protein were obtained by stable  cotransfection with 
p53cG(va1135) and pBabe-puro. A number of clones were 
screened by immunofluorescence and three of the p53Va1135 
highest  expressors  (C2-tsp53#15,  C2-tsp53#16,  and  C2- 
tsp53#17) were selected for the following experiments, to- 
gether with one puro-expressing clone (C2-puro#2) (Fig. 
Figure 2.  Inhibition of granulocytic differentiation  in p53Va1135- 
and DD-expressing 32D cells. (A) Cytocentrifuge preparations  of 
32D-transfectants maintained in the presence of IL-3 or G-CSF 
were stained with May-Grunwald  Giemsa to evaluate  morpho- 
logical features  (original magnification 630). (B) The indicated 
cells were incubated for 8 d in the presence of G-CSF and pre- 
pared as in A. Two hundred cells were counted from each cyto- 
centrifuge preparation to calculate the percentage of undifferen- 
tiated blasts, partially differentiated  myelocytes, and terminally 
differentiated granulocytes. 
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of p53 from metabolically labeled 
C2C12 by conformation-specific 
moAbs. Total cell lysate was di- 
vided in three aliquots and incu- 
bated with the indicated moAbs. 
H-2Kb is  a  moAb that  recog- 
nizes a major histocompatibility 
complex class I antigen. This an- 
tigen is not expressed on C2C12 
cells. PAb246 is an anti-wild-type 
p53 moAb while  PAb240  is an 
anti-mutant p53 moAb. 
4, A-D). Since C2C12 subclones can exhibit variable abili- 
ties to differentiate, polyclonal populations were obtained 
by transfection  of vectors encoding  either  the neo resis- 
tance  gene  and  p53Va1135 mutant  or  the  neo  resistance 
gene  alone  (C2-tsp53  Mix  and  C2-neo Mix).  Exogenous 
p53 expression was detected by immunofluorescence (Fig. 
4, E  and F). Muscle differentiation was induced by serum 
starvation and morphologically differentiated, MHC-posi- 
tive cells were revealed by phase contrast (not shown) and 
indirect immunofluorescence analyses after 72 h incubation 
in SF-medium (Fig. 5 A). A  reduction of ~60% in the dif- 
ferentiation indices was observed in p53Vap35-expressing 
clonal  and  polyclonal cell populations,  cultured  at 37°C, 
compared to parental, puro- and neo-controls. This differ- 
ence was maintained even after an incubation of 5 d in SF- 
medium  (Fig.  5  B).  Thus,  interference  with endogenous 
wt-p53 does not only impair hematopoietic differentiation, 
but also the differentiation of a completely different histo- 
type such as skeletal muscle. Since p53Va1135 partially re- 
tains wild-type activity at 37°C  (Martinez et al.,  1991), in 
an  attempt to increase  suppression  of differentiation  we 
repeated the  experiments at 39.5°C.  However, no differ- 
ence  was  found  in  differentiation  indices  between  37°C 
and 39.5°C (data not shown). 
C2C12 Cell Differentiation Can be Restored by 
Reverting the p53Va1135 Mutant Configuration 
The p53Va1135 mutant can cooperate with activated ras in 
cell  transformation  (Michalovitz  et  al.,  1990).  Thus,  we 
asked whether p53Va1135 mutant expression inhibited myo- 
tube formation by inducing permanent cell modifications 
through genomic instability, or, alternatively, the persist- 
ing expression of dominant-negative p53 protein is neces- 
sary for suppression of differentiation. The p53VallaS-posi- 
tive C2C12 cells were shifted to 32°C to generate wt-p53 
configuration  of  the  temperature-sensitive  p53  protein, 
and incubated in GM or SF media. Differently from what 
was observed in tumor-derived cell lines (Shaulsky et al., 
1991; Feinstein et al., 1992; Soddu et al., 1994), overexpres- 
sion of wt-p53 alone was not sufficient to induce differenti- 
ation in the presence of serum (data not shown). However, 
in differentiation-promoting conditions  (i.e., SF-medium) 
Figure 4.  Exogenous p53VaP 35 mutant expression in C2C12 cells. 
C2-tsp53#15 (A),  C2-tsp53#16 (B), C2-tsp53#17 (C),  C2-puro#2 
(D), C2-tsp53 Mix (E), and C2-neo Mix (F) cells were cultured in 
35-ram Petri dishes, fixed, and permeabilized,  p53 overexpression 
was  detected  by  indirect  immunofluorescence  with  moAb 
PAb122 (original magnification 400). 
myotube formation was observed which, in the case of the 
C2-tsp53#15  and C2-tsp53#16  clones, was even increased 
in comparison to the control cells after 5 d  of stimulation 
(Fig.  5  C).  These  data  show  that  p53Vap35-expressing 
C2C12 cells do not permanently lose their ability to differ- 
entiate. 
As shown in Fig. 5 C, incubation at 32°C reduces the dif- 
ferentiation index of control cells and increases the  time 
necessary for their  differentiation  (not  shown),  probably 
because  of a  general  slow down  of cell  metabolism. To 
avoid temperature  and  clone-to-clone variability, we  in- 
fected C2C12 cells with a wt-p53-recombinant adenovirus. 
The  El-deleted  d1312 adenovirus  was  used  as  negative 
control.  Expression  of  exogenous  p53  was  assessed  by 
Western blotting (data not shown). Acceleration of differ- 
entiation was observed in the Adp53-infected cells, com- 
pared to controls, whereas similar differentiation  indices 
were reached at the 72-h endpoint (Fig. 5  D). Taken to- 
gether, these data are suggestive of a rate-limiting function 
for wt-p53 protein in muscle cell differentiation, at least in 
the C2C12 model. 
Soddu et al. p53 Role in Cell Differentiation  197 Figure 5.  Inhibition of muscle differentiation in p53Val135-expressing  C2C12 cells. The indicated C2C12-transfectants or infected cells 
were induced to differentiate by serum starvation. (A) Myosin heavy chain (MHC) expression was detected by indirect immunofluores- 
cence. HOECHST staining was used to count nuclei (original magnification 200). (B) The indicated cells were induced to differentiate 
at the nonpermissive temperature of 37°C. Differentiation indices were calculated as described in Materials and Methods by counting 
two hundred nuclei from each sample. (C) The indicated cells were induced to differentiate at the permissive temperature of 32°C. Dif- 
ferentiation indices were calculated as in Fig. 5 B. (D) Time course analysis of differentiation in C2C12 cells infected with wt-p53-recom- 
binant, or El-deleted d1312 adenoviruses. 
Interference with or Overexpression of wt-p53 Do Not 
Modify Cell Viability during C2C12 Differentiation 
Incubation of C2C12 cells in SF-medium to induce differ- 
entiation usually produces some cell death. Since p53 is in- 
volved in apoptotic cell death mediated by different stim- 
uli (Lowe et al., 1993b; Gottlieb et al., 1994; Morgenbesser 
et al., 1994), it was conceivable that the changes in differ- 
entiation indices observed at 37°C and 32°C in p53VaP 35- 
expressing cells was due to a variation in the total number 
of surviving cells, which would modify the  ratio used  to 
calculate the differentiation index (see Materials and Meth- 
ods), rather than a  real change in the cell capacity to un- 
dergo differentiation. To test this possibility, C2-tsp53 Mix 
and  C2-neo  Mix  cells were  incubated  in  SF-medium  at 
39.5°C or 32°C and cell viability was daily evaluated by try- 
pan  blue  exclusion (Fig. 6,  39.5°C  and  32°C).  No  differ- 
ences  in death rates were  found between  p53VaP 35- and 
neo-expressing cells at either temperature.  Similar results 
were obtained with the recombinant-adenovirus-infected 
C2C12 cells (Fig. 6, 37°C). These data show that the differ- 
ences we  found  in  differentiation indices are  not  due  to 
p53-mediated alterations of death rates. 
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Figure 6.  Viability curves of transduced C2C12 cells upon induc- 
tion of differentiation. The indicated cells were stimulated to dif- 
ferentiate at the reported temperatures,  as described in the leg- 
end to Fig. 5. Cell viability was daily evaluated  by trypan blue 
exclusion. 
Inhibition of Cell Differentiation by 
Interference with Wt-p53 Is Not Coupled with Stimulation 
of Cell Proliferation 
Terminal differentiation of many cell types, such as granu- 
locytes and myocytes, entails growth arrest (Baserga, 1985; 
Crescenzi et al.,  1995). A  number of activated oncogenes 
can inhibit 32D or C2C12 differentiation (Rovera et al., 
1987; Mavilio et al., 1989; Kruger and Anderson, 1991; Pa- 
tel et al.,  1993; for review see Alem~ and Tatb, 1994), at 
least in part through their ability to maintain the cells in a 
proliferative state. Moreover, wt-p53-induced growth ar- 
rest  is  well  documented  in  several  biological  systems 
(Baker et al., 1990; Kuerbitz et al., 1992). Thus, we asked 
whether the  expression of p53VaP as mutant  or DD-p53 
miniprotein interfered with growth arrest in the Go phase 
Table I. Percentages of Cells in the Different Phases of the Cell 
Cycle 
IL-3 Treatment  G-CSF Treatment* 
Transfectants  G~  S  G2/M  Gt  S  G2/M 
32D-neo#12  36.8  57.3  5.9  60.2  37.1  2.7 
32D-tsp53#6  26.9  66.6  6.5  57.6  39.6  2.8 
32D-tsp53#8  34.3  60.4  5.3  43.2  50.6  6.2 
32D-tsp53#10  34.5  60.3  5.2  43.0  51.6  5.5 
32D-puro#1  27.9  64.8  7.3  61.0  37.9  1.1 
32D-DD#2  29.0  64.3  6.7  66.2  31.0  2.8 
32D-DD#4  25.8  69.2  4.9  49.0  46.0  5.0 
32D-DD#10  30.3  65.2  4.5  47.6  48.9  3.5 
32D-DD#13  25.9  68.5  5.6  57.8  38.8  3.4 
*The ceils were treated with G-CSF  for 8 d as indicated in Materials and Methods. 
of the cell cycle, typical of cell differentiation. 32D trans- 
fectants were incubated for 8 d at 37°C in the presence of 
G-CSF as described above and stained with propidium io- 
dide.  DNA  content  was  evaluated  by  cytofluorimetric 
analysis. Table I  shows similar levels of accumulation in 
the G0/G1 phase of the cell cycle of p53Va1135- or DD-p53- 
positive and control cells. DNA content analysis is difficult 
to perform on multinucleated myotubes; thus, for C2C12 
cells,  proliferation rates  were  determined.  As  shown  in 
Fig. 7 A, all cell populations similarly reduced their prolif- 
eration  rates  after  serum  withdrawal,  independently  of 
their subsequent ability to differentiate. 
It  has  been  recently  shown  that  the  expression  of 
p21 (wAvl/clm) inhibitor of cyclin-dependent kinases is in- 
duced during differentiation of hematopoietic and muscle 
cells, independently of p53 (Steinman et al., 1994; Halevy 
et al., 1995). On the basis of these observations, our domi- 
nant-negative p53-expressing C2C12  cells, which  do not 
differentiate but stop  growing, should express increased 
levels of p21 upon SF-stimulation. A  time-course analysis 
of p21  transcription was performed on C2-neo Mix  and 
C2-tsp53 Mix cells maintained in GM- or SF-medium. As 
expected, an upregulation of p21 starting 18 h from serum 
withdrawal was found in both cell populations (Fig. 7 B). 
Taken  together,  these  data  indicate  that  interference 
with wt-p53 specifically inhibits cell differentiation with- 
out affecting the competence for withdrawal from the cell 
cycle. 
Transcriptionally Active p53 Protein Is Induced during 
Muscle Differentiation 
We sought to investigate whether differentiation is associ- 
ated with induction of transcriptionally active p53 protein. 
For this purpose we stably transfected C2C12 cells with 
two reporter vectors carrying multiple copies of the p53 
consensus-binding  sequence-PG13CAT or of a  p53  non- 
binding  site-MG15CAT  (see  Materials  and  Methods). 
CAT gene-positive clones were screened by polymerase 
chain reaction amplification (not shown) and the activity 
of endogenous p53  protein  on  the  two vectors was  as- 
sessed by UV-light exposure (Lu and Lane, 1993).  As ex- 
pected,  a  strong  upregulation  of transcription  was  ob- 
served only in PG13CAT-carrying cells (data not shown). 
When  the  same  clones were  stimulated  to  differentiate 
into myotubes, dramatically increased CAT protein levels 
Soddu et al. p53 Role in Cell Differentiation  199 Figure 7.  Growth rate analyses of transduced  C2C12 cells. (A) 
The indicated cells were maintained in growing condition (GM) 
(white symbols), or in differentiation condition (SF) (black sym- 
bols). Cell numbers were determined in duplicate, at daily inter- 
vals, by trypan blue exclusion. Multinucleated cells were counted 
as single cells. The analysis in SF was stopped after 3 d because of 
the  appearance  of numerous  multinucleated  cells  in  the  C2- 
puro#2 control. (B) Kinetics of p21 (wAFl/cIvl) transcription  upon 
SF stimulation of C2-neo Mix and C2-tsp53 Mix cells at 37°C. 
were found (Fig. 8 A). The differences observed between 
PG-cat#6 and PG-cat#15 are probably due to clonal vari- 
ability in  differentiation kinetics.  These  data  show  that 
during muscle differentiation there is an increase in tran- 
scriptionally  active  p53  protein.  This  observation  is  in 
keeping  with  the  reported  upregulation  of p53  mRNA 
during C2 muscle differentiation (Halevy et al., 1995), and 
it is consistent with a physiological role of p53 in cell dif- 
ferentiation. 
To confirm that the dominant-negative mutant we used 
to interfere with endogenous p53 is able to suppress the 
wt-p53 transcriptional activity, we stably transfected PG- 
cat#6 and PG-cat#15 cells with the p53Val a35 mutant and 
determined  CAT  protein  levels  upon  SF-stimulation  at 
37°C and 32°C. As expected, a reduction of CAT expres- 
sion was observed in the p53Vala35-expressing cells, com- 
pared  to  neo-controls,  when  the  experiment  was  per- 
formed at 37°C (Fig. 8 B). Opposite results were obtained 
at 32°C (Fig. 8 B). 
The Transcriptional Activity of  p53 Is Necessary to 
Induce Cell Differentiation 
To evaluate  whether the  p53  transcriptional  activity we 
observed in C2C12 cells during their maturation is neces- 
sary for the induction of differentiation, we compared the 
effects of two  different p53  mutants,  one  in  the  DNA- 
binding domain  (p53Va1135), and one in both the DNA- 
binding and transacting domains (p53Val135-22/23).  K562 
cells, which do not express endogenous p53 protein and 
can be induced to differentiate along the erythroid path- 
way  by  wt-p53  overexpression  (Feinstein  et  al.,  1992), 
were  chosen  for this  experiment.  Cell  clones  were  ob- 
tained by stable transfection. The expression of the two 
different mutants was analyzed by Western blotting (Fig. 9 
A).  Four  p53Va1135- and  four  p53Va1135-22/23-positive 
clones (see Materials and Methods) were selected for the 
following experiments among those expressing the highest 
and comparable levels of the transduced proteins, together 
with one neo-expressing clone (K-neo#1). Differentiation 
induction was assessed by benzidine staining of hemoglo- 
bin-expressing  ceils.  In  agreement  with  the  finding  re- 
ported by Feinstein et al. (1992), when our K-tsp53 trans- 
fectants  were  shifted  to  32°C to  express  wt-like  p53 
protein,  spontaneous  erythroid  differentiation  was  ob- 
served (Fig. 9 B). In contrast, no differentiation was found 
in the K-ts22/23 transfectants incubated at 32°C for as long 
as three weeks, indicating that the DNA-binding activity 
of p53 is not sufficient to induce cell differentiation, and 
transcriptional activation is required. 
Discussion 
Experiments performed with tumor cells are providing in- 
creasing evidence of p53 involvement in cell differentia- 
tion (Shaulsky et al., 1991; Feinstein et al., 1992; Brenner 
et al., 1993; Kemp et al., 1993; Soddu et al., 1994; Pan et al., 
1994). Moreover, enhanced expression of p53 protein was 
observed during differentiative processes as diverse as he- 
matopoiesis and spermatogenesis (Kastan et al., 1991a; A1- 
mon et al., 1993). These findings are in apparent contrast 
with  the  normal  development of p53-null  mice  (Done- 
hower et al.,  1992).  However, targeted deletions of genes 
whose role in normal differentiation is well established do 
not overtly affect ontogenesis. This indicates that the role 
of important genes in normal development may escape de- 
tection due to functional redundancy. Notably, knock-outs 
of MyoD or Myf-5 genes, that encode skeletal muscle-spe- 
cific regulatory factors, generate completely normal mice, 
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sion. The indicated C2C12 clones were analyzed 
after incubation in GM or at the indicated times 
after serum withdrawal. (A) The transacting ac- 
tivity of endogenous wt-p53 of parental  C2C12 
cells is measured upon induction of differentia- 
tion. (B) The endogenous wt-p53 activity showed 
in A was reduced by p53Va1135 expression in mu- 
tant configuration (37°C) and increased in wild- 
type configuration (32°C). 
or mice with normal muscles, respectively (Rudnicki et al., 
1992; Braun et al., 1992). Thus, to demonstrate that wt-p53 
plays a role in physiological cell differentiation, we inter- 
fered with the endogenous wt-p53 protein of cells already 
determined,  such  as  nontransformed myeloid precursor 
and myoblast cells. We found that expression of p53 domi- 
nant-negative proteins modified neither cell morphology 
nor proliferation rates, as long as the transfected cells were 
maintained in an undifferentiated state. However, when 
the transfectants were induced to differentiate, both 32D 
and C2C12 cells showed a striking reduction in their abil- 
ity  to  undergo  granulocyte  or  myotube  differentiation, 
strongly indicating that wt-p53 is involved in cell differen- 
tiation, although this function must be  somehow surro- 
gated in p53-null mice. 
We obtained complementary evidence in favor of a role 
for p53 in differentiation by overexpressing wt-p53 protein 
in C2C12 cells. Particularly in the p53-recombinant adeno- 
virus-infected cells, constantly maintained at 37°C, an ac- 
celeration of myotube formation was observed after serum- 
starvation. Moreover, induction of C2C12 differentiation 
associated with increased transcriptional activity of the en- 
dogenous p53.  This result is consistent with the observa- 
tion  made  in  differentiating epidermal  keratinocytes in 
which increased p53-mediated transcriptional activity was 
found (Weinberg et al., 1995). We obtained data support- 
ing the relevance of p53 transacting activity.in modulating 
cell  differentiation by  overexpressing  two  p53  mutants 
into p53-negative K562 cells. We found that only wt-p53 
protein  induces  erythroid differentiation of these  cells, 
while the p53 mutant that conserves the DNA-binding ca- 
pacity but lacks the transacting activity is no longer able to 
stimulate differentiation. 
In both hematopoietic and muscle terminal differentia- 
tion, cells permanently withdraw from the cell cycle. Since 
wt-p53 can induce growth arrest in tumor cells (Baker et al., 
1989; Michalovitz et al., 1990; Yin et al.,  1992), we asked 
whether interference with endogenous wt-p53 maintained 
32D and C2C12 cells in the mitotic cycle, consequently in- 
hibiting cell differentiation. Proliferation rate evaluations 
showed that differentiation-promoting conditions did in- 
duce withdrawal from the cell cycle and upregulation of 
p21 ~wAF'I/c~PI~  in dominant-negative p53-expressing as well 
as control cells;  this indicates that inhibition of endoge- 
nous p53 interferes directly with cell differentiation inde- 
pendently of any effects on the cell cycle. These results are 
in agreement with those obtained with some leukemias in 
which p53-mediated maturation was not preceded by G1 
arrest (Shaulsky et al., 1991; Feinstein et al., 1992; Soddu 
et al., 1994). They are also in agreement with recent find- 
ings indicating that p21, a likely determinant of the growth 
arrest associated with muscle terminal differentiation, can 
be upregulated by MyoD independently of p53  (Halevy 
et al., 1995; Parker et al., 1995). 
The  functions  of  wt-p53  in  mediating  apoptotic  cell 
death (Lowe et al., 1993a; Clarke et al., 1993), growth fac- 
tor dependence (Yonish-Rouach et al., 1991; Gottlieb et al., 
1994),  and  growth  arrest  consequent  to  DNA  damage 
(Kuerbitz et al.,  1992, Lowe et al., 1993b;  Lu and Lane, 
1993) are well defined. In this study we demonstrate that 
p53  plays a role in cell differentiation. It is possible that 
p53 is a cofactor in completely divergent pathways regulat- 
ing all of these biological events. Alternatively, a link be- 
tween these pathways can be hypothesized. Tissue  and 
organ homeostasis are characterized, during both ontoge- 
nesis and adult life, by a well controlled balance of prolif- 
Soddu et al. p53 Role in Cell Differentiation  201 Figure 9.  Induction of erythroid differentiation in K562 cells trans- 
fected with temperature-sensitive p53Val ~35 mutant or p53Val ~3s- 
22/23 double mutant. (A) Western blot analysis of exogenous p53 
mutant expression.  (B) The indicated  clones were incubated at 
the nonpermissive  (37°C) or permissive  (32°C) temperature for 
one week. Hemoglobin was detected by benzidine reaction. Four 
hundred cells were counted by light microscopy to calculate  the 
percentage of benzidine-stained  cells. 
eration, apoptosis, and differentiation. Hematopoiesis is a 
paradigmatic example of homeostasis. Stem cells can be in- 
duced to proliferate by some cytokines, and to differenti- 
ate by others. The required number of cells can be achieved 
by balancing  apoptosis  and  proliferation  (Dexter  et  al., 
1977; Metcalf, 1989; Williams et al., 1990).  It can be specu- 
lated that p53 acts at a cross-road linking the network of 
signals  that  regulate  this  homeostasis.  Fig.  10  outlines  a 
possible role for p53 in  the  regulation  of hematopoiesis. 
Proliferating stem cells might receive an early differentia- 
tion signal that activates p53.  Indeed, increased levels of 
p53 protein have been found in the course of hematopoi- 
etic maturation (Kastan et al., 1991a). Moreover, our data 
show that transiently increased levels of transcriptionally 
active  p53  protein  follow  differentiation  induction  in 
C2C12  cells.  Since DNA-breaks have been found during 
hematopoietic  and  muscle  maturation  (Johnstone  and 
Williams, 1982; Farzaneh et al., 1982),  early differentiation 
signals  might  in  part  function  through  the  induction  of 
such breaks. In other words, it is possible that p53 activity 
is induced through the presence of DNA-breaks, both in 
stress and physiological conditions. This would match the 
recent observation that ~-irradiation induces immunoglob- 
ulin K light chain gene expression in pre-B lymphoid cells 
(Aloni-Grinstein et al., 1995).  The increased levels of p53 
now make the cells dependent on the presence of growth 
or differentiation factors. If these factors are available, the 
levels of active p53 decrease and the cells complete their 
differentiation  program.  In  contrast,  in  the  absence  of 
these factors, the levels of p53 remain high and the cells 
die by apoptosis. This p53-mediated dependence on growth 
and  differentiation  factors was  shown  in  M1  and  DA-1 
cells in which overexpression of wt-p53 induces apoptosis 
that can be inhibited by supplementing specific cytokines 
(Yonish-Rouach et al., 1991; Gottlieb et al., 1994).  In addi- 
tion, overexpression of wt-p53 in 32D cells has no effect as 
long as  the  cells  are  maintained  in  their  normal culture 
conditions, but it accelerates apoptosis after interleukin-3 
withdrawal, suggesting a rate-limiting effect of p53 in apop- 
totic cell death (Blandino et al., 1995). The fact that C2C12 
cells overexpressing wt-p53 accelerate their differentiation 
rate only in the presence of the differentiation-promoting 
conditions, is also in agreement with this thesis. 
Figure 10.  Model for the role 
of p53 in hematopoietic ho- 
meostasis.  Expression  of wt- 
p53  protein  might  increase 
during  early  differentiation 
steps. These increased  levels 
might  be induced  by DNA- 
break  formation.  The  cells 
that now express  high levels 
of p53 become dependent on 
growth or differentiation  fac- 
tors.  If  these  factors  are 
available,  the level of active 
p53  decreases  and  the  cells 
can  differentiate.  In the  ab- 
sence  of  these  factors,  p53 
level  remains  high  and  the 
cells die by apoptosis. 
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